- Home
- FIG vs AXSM Comparison
FIG vs AXSM Comparison
Compare FIG & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | AXSM |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | 1886 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 12.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FIG | AXSM |
|---|---|---|
| Price | $23.91 | $210.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | $50.50 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 18.2M | 646.3K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.18 | $57.24 |
| Revenue Next Year | $20.22 | $55.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $102.69 |
| 52 Week High | $82.60 | $260.19 |
Technical Indicators
Market Signals| Indicator | FIG | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 37.99 |
| Support Level | $20.28 | $148.87 |
| Resistance Level | $24.76 | $238.57 |
| Average True Range (ATR) | 1.64 | 9.17 |
| MACD | 0.19 | -2.60 |
| Stochastic Oscillator | 32.87 | 19.61 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.